X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Anti-viral activity OT-101 (trabedersen), in an in vitro antiviral testing which has a 50% effective concentration of 7.6 µg/mL and is not toxic at highest dose of 1000 µg/mL giving safety index value of >130, is considered highly active and on par or superior to Remdesivir.
Lead Product(s): Trabedersen
Therapeutic Area: Oncology Product Name: OT101
Highest Development Status: PreclinicalProduct Type: Large molecule
Recipient: Oncotelic Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 28, 2022
Details:
Mateon has completed the enrollment of its sentinel Part 1 and Part 2 COVID-19 patients which allows for the continuing expansion to the targeted 18 patients in part 1 and 18 patients in part 2. OT-101 is an antisense against the host TGF-β protein.
Lead Product(s): Trabedersen,Artemisinin
Therapeutic Area: Infections and Infectious Diseases Product Name: OT-101
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Oncotelic
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 08, 2021
Details:
The funds will be used to advance the company’s lead A2BR-selective antagonist TT-702 into the clinic as well as to build the company’s pipeline.
Lead Product(s): TT-702
Therapeutic Area: Oncology Product Name: TT-702
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Oceanpine Capital
Deal Size: $30.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing February 23, 2021
Details:
C-001 is a Phase 2 randomized, placebo-control study to evaluate safety and efficacy of OT-101 in combination with standard of care on two patient cohorts – 1) mild or moderate disease, and 2) severe disease requiring mechanical ventilation or intubation.
Lead Product(s): Trabedersen,Undisclosed
Therapeutic Area: Infections and Infectious Diseases Product Name: OT-101
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 30, 2020
Details:
OXi4503 in combination with standard chemotherapy drug cytarabine was generally well tolerated by adult AML patients and a maximum tolerated dose level of OXi4503 was identified as the recommended dose for further clinical development of this novel two-drug combination.
Lead Product(s): Combretastatin A1 Diphosphate
Therapeutic Area: Oncology Product Name: OXi4503
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 16, 2020
Details:
ARTI19 is designed to rapidly establish the clinical efficacy of Artemisinin in mild and moderate COVID-19 patients. In-vitro, the medical grade version of the supplement has proven potency and safety similar to Remdesivir with an EC50 = 0.45 ug/ml and Safety Index = 140.
Lead Product(s): Artemisinin
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Recipient: Asili Research Alliance
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership July 20, 2020
Details:
Mateon Therapeutics announced that it will fund observational studies for Artemisinin, an herbal supplement, that demonstrated potent in vitro activity against SARS-CoV-2, the COVID-19 virus.
Lead Product(s): Artemisinin
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Recipient: Undisclosed
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Funding July 13, 2020
Details:
Mateon was approved to use the platform following a review of the program as part of IBM Watson Health’s effort to help support and accelerate promising clinical COVID-19 candidates.
Lead Product(s): Trabedersen
Therapeutic Area: Infections and Infectious Diseases Product Name: OT-101
Highest Development Status: PreclinicalProduct Type: Large molecule
Recipient: IBM Watson Health
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement June 24, 2020
Details:
GMP and Mateon are working to ensure safety and efficacy of OT-101 and Artemisinin for COVID-19 patients. OT-101 is an antisense against host TGF-β protein required for viral replication.
Lead Product(s): Trabedersen
Therapeutic Area: Infections and Infectious Diseases Product Name: OT-101
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 22, 2020
Details:
OT-101 has demonstrated robust efficacy against pancreatic cancer, glioblastoma, and melanoma during phase 2 clinical trials. The demonstration that OT-101 will synergize with IL-2 further demonstrate its utility as adjunct to other immunotherapies.
Lead Product(s): Trabedersen,Aldesleukin
Therapeutic Area: Oncology Product Name: OT-101
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Autotelic BIO
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement June 10, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
